DISCUSSION Late cardiotoxic effects of doxorubicin are an increasing problem for large numbers of patients who survive cancer. This cardiotoxicity is often progressive and disabling. In a retrospective study of 399 patient records, CHF and cardiomyopathy were found to be dose-dependent, and the incidence of these complications increased considerably when the cumulative dose of the [...]
Out of 120 eligible patients receiving doxorubicin combination therapy at Howard during the study period, 100 patients were evaluable, all of whom were African American (65% women, 35% men, median age 46 years, range 32-84 years). Fifteen patients had hypertension, and 10 were diabetics. None of the patients had history of CHF or coronary artery [...]
A retrospective survey of the Howard University Hospital cancer registry during 1997-2001 was conducted to identify all patients who underwent Adriamycin-based combination chemotherapy. Charts were reviewed to find evaluable patients who had records of the cumulative dose of doxorubicin and assessment of clinical cardiac status and echocardiogram both before therapy and at one- to four [...]
INTRODUCTION In 1957 streptomyces peucetius was isolated from southern Italian soil. The compound 1, 4-hydroxydaunomycin was produced by a variant strain and called Adriamycin (Adria) because of the proximity of the parent strain source to Adriatic Sea. Doxorubicin hydrochloride, the generic name for Adriamycin, has a leading role in the treatment of hematological malignancies and [...]
